Total Payments
$416,944
2024 Payments
$54,917
Companies
46
Transactions
546
Medicare Patients
7,296
Medicare Billing
$1.1M
Payment Breakdown by Category
Consulting$246,288 (59.1%)
Other$85,554 (20.5%)
Travel$39,977 (9.6%)
Research$31,677 (7.6%)
Food & Beverage$13,204 (3.2%)
Education$243.61 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $246,288 | 105 | 59.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $76,792 | 35 | 18.4% |
| Travel and Lodging | $39,977 | 83 | 9.6% |
| Unspecified | $31,677 | 10 | 7.6% |
| Food and Beverage | $13,204 | 286 | 3.2% |
| Honoraria | $7,200 | 7 | 1.7% |
| Long term medical supply or device loan | $1,562 | 16 | 0.4% |
| Education | $243.61 | 4 | 0.1% |
Payments by Type
General
$385,267
536 transactions
Research
$31,677
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $112,156 | 105 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $55,264 | 67 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $49,400 | 73 | $0 (2024) |
| Gilead Sciences, Inc. | $42,770 | 44 | $0 (2024) |
| Eli Lilly and Company | $37,579 | 17 | $0 (2024) |
| PFIZER INC. | $21,929 | 36 | $0 (2024) |
| F. Hoffmann-La Roche AG | $19,917 | 14 | $0 (2023) |
| Puma Biotechnology, Inc. | $18,561 | 35 | $0 (2023) |
| Genentech USA, Inc. | $10,084 | 16 | $0 (2023) |
| Myriad Genetic Laboratories, Inc. | $5,488 | 10 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $54,917 | 73 | Gilead Sciences, Inc. ($35,577) |
| 2023 | $43,934 | 55 | PFIZER INC. ($13,442) |
| 2022 | $32,625 | 53 | AstraZeneca Pharmaceuticals LP ($10,609) |
| 2021 | $34,767 | 36 | Lilly USA, LLC ($5,600) |
| 2020 | $42,646 | 39 | Eli Lilly and Company ($17,500) |
| 2019 | $99,392 | 91 | Lilly USA, LLC ($53,914) |
| 2018 | $58,048 | 107 | Puma Biotechnology, Inc. ($18,202) |
| 2017 | $50,616 | 92 | Lilly USA, LLC ($23,613) |
All Payment Transactions
546 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $535.00 | General |
| 12/18/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $4,070.00 | General |
| Category: ONC | ||||||
| 12/17/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $1,440.00 | General |
| Category: ONC | ||||||
| 12/12/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: ONC | ||||||
| 12/12/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $113.52 | General |
| Category: ONC | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $72.78 | General |
| 12/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $108.95 | General |
| 12/11/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $76.80 | General |
| 12/11/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $17.45 | General |
| Category: ONC | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $11.92 | General |
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $42.32 | General |
| 12/08/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $36.30 | General |
| Category: Oncology | ||||||
| 12/06/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $120.42 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $12.40 | General |
| Category: NONE | ||||||
| 11/27/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 11/21/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $25.75 | General |
| Category: NONE | ||||||
| 11/19/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $12,000.00 | General |
| Category: ONC | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $1,337.50 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $480.00 | General |
| Category: ONC | ||||||
| 10/12/2024 | BioNTech SE | — | Food and Beverage | In-kind items and services | $81.46 | General |
| 10/01/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $535.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $10,779 | 1 |
| NEOMONARCH - A PHASE 2 NEOADJUVANT TRIAL COMPARING THE BIOLOGICAL EFFECTS OF 2 WEEKS OF ABEMACICLIB -LY2835219- IN COMBINATION WITH ANASTROZOLE TO THOSE OF ABEMACICLIB MONOTHERAPY AND ANASTROZOLE MONOTHERAPY AND EVALUATING THE CLINICAL ACTIVITY AND SAFETY OF A SUBSEQUENT 14 WEEKS OF THERAPY WITH ABEMACICLIB IN COMBINATION WITH ANASTROZOLE IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER | Eli Lilly and Company | $3,664 | 1 |
| EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $3,619 | 1 |
| Practice- and provider-level inequities in next-generation sequencing (NGS) testing by race/ethnicity for patients (pts) with advanced non-small cell lung cancer (aNSCLC) treated in the Community Setting | F. Hoffmann-La Roche AG | $898.89 | 1 |
| Paclitaxel monotherapy dosing and administration patterns in 1L mTNBC in the United States | F. Hoffmann-La Roche AG | $729.20 | 1 |
| Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | F. Hoffmann-La Roche AG | $695.36 | 2 |
| EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | Eli Lilly and Company | $488.20 | 1 |
| A PHASE IB, OPEN-LABEL STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY IN COMBINATION WITH TRASTUZUMAB EMTANSINE OR WITH TRASTUZUMAB AND PERTUZUMAB WITH AND WITHOUT DOCETAXEL IN PATIENTS WITH HER2-POSITIVE BREAST CANCER AND ATEZOLIZUMAB WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE IN HER2-NEGATIVE BREAST CANCER | F. Hoffmann-La Roche AG | $303.90 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 40 | 1,800 | 8,183 | $541,599 | $128,839 |
| 2022 | 28 | 1,754 | 5,396 | $603,112 | $142,318 |
| 2021 | 24 | 1,659 | 11,352 | $983,999 | $241,958 |
| 2020 | 42 | 2,083 | 54,400 | $2.3M | $578,228 |
Total Patients
7,296
Total Services
79,331
Medicare Billing
$1.1M
Procedure Codes
134
All Medicare Procedures & Services
134 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 217 | 442 | $180,944 | $34,736 | 19.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 13 | 1,200 | $84,444 | $22,346 | 26.5% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 26 | 140 | $9,800 | $11,015 | 112.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 77 | 87 | $39,567 | $8,065 | 20.4% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 11 | 2,015 | $22,024 | $4,805 | 21.8% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2023 | 191 | 559 | $16,552 | $4,562 | 27.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 196 | 596 | $16,211 | $4,456 | 27.5% |
| 80076 | Liver function blood test panel | Office | 2023 | 171 | 498 | $14,243 | $3,927 | 27.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 162 | 445 | $12,683 | $3,716 | 29.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 48 | 59 | $17,040 | $3,029 | 17.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 19 | 19 | $13,374 | $2,926 | 21.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 20 | 22 | $12,649 | $2,657 | 21.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 16 | 29 | $11,186 | $2,628 | 23.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 20 | $11,246 | $2,502 | 22.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 66 | 108 | $9,813 | $2,306 | 23.5% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 11 | 13 | $10,691 | $2,232 | 20.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 15 | 22 | $8,776 | $1,863 | 21.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 33 | 35 | $6,945 | $1,585 | 22.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 27 | 33 | $7,282 | $1,500 | 20.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 17 | 21 | $5,326 | $1,112 | 20.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 25 | 39 | $3,781 | $809.72 | 21.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 13 | $3,332 | $753.19 | 22.6% |
| J0640 | Injection, leucovorin calcium, per 50 mg | Office | 2023 | 12 | 218 | $2,749 | $691.17 | 25.1% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 17 | 22 | $4,262 | $672.21 | 15.8% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 35 | 43 | $2,080 | $489.21 | 23.5% |
About Dr. Gregory Vidal, M.D
Dr. Gregory Vidal, M.D is a Medical Oncology healthcare provider based in Germantown, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/16/2010. The National Provider Identifier (NPI) number assigned to this provider is 1730403072.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Vidal, M.D has received a total of $416,944 in payments from pharmaceutical and medical device companies, with $54,917 received in 2024. These payments were reported across 546 transactions from 46 companies. The most common payment nature is "Consulting Fee" ($246,288).
As a Medicare-enrolled provider, Vidal has provided services to 7,296 Medicare beneficiaries, totaling 79,331 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 134 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology
- Location Germantown, TN
- Active Since 03/16/2010
- Last Updated 11/08/2017
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1730403072
Products in Payments
- VERZENIO (Drug) $83,493
- Trodelvy (Drug) $41,707
- PIQRAY (Drug) $30,927
- KISQALI (Drug) $23,007
- TECENTRIQ (Biological) $20,322
- IBRANCE (Drug) $19,791
- Nerlynx (Drug) $18,302
- ENHERTU (Biological) $11,220
- LYNPARZA (Drug) $9,560
- FASLODEX (Drug) $8,114
- myChoice CDx (Device) $5,363
- Cabometyx (Drug) $5,101
- Herceptin (Biological) $4,903
- Orserdu (Drug) $4,583
- TUKYSA (Drug) $3,450
- Lenvima (Drug) $2,622
- Perjeta (Biological) $2,355
- XGEVA (Biological) $1,947
- Truqap (Drug) $1,605
- Oral Paclitaxel (Drug) $1,500
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Germantown
Mr. Jason Chandler, M.d, M.D
Medical Oncology — Payments: $190,234
Medical Oncology $190,234
Daniel Vaena, Md, MD
Medical Oncology — Payments: $107,350
Medical Oncology $107,350
Kurt Tauer, Md, MD
Medical Oncology — Payments: $33,253
Medical Oncology $33,253
Ronald Lawson, Md, MD
Medical Oncology — Payments: $1,049
Medical Oncology $1,049
Dr. Jacob Adashek, Do, DO
Medical Oncology
Medical Oncology